Shenzhen - Delayed Quote CNY
Winner Medical Co., Ltd. (300888.SZ)
51.56
+0.69
+(1.36%)
At close: 3:04:55 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
9.67B
8.98B
8.19B
11.35B
8.04B
Cost of Revenue
5.07B
4.73B
4.17B
5.97B
4.03B
Gross Profit
4.60B
4.25B
4.01B
5.38B
4.01B
Operating Expense
3.46B
3.27B
3.07B
3.19B
2.70B
Operating Income
1.14B
973.98M
938.92M
2.19B
1.30B
Net Non Operating Interest Income Expense
44.26M
59.02M
69.49M
70.50M
136.45M
Pretax Income
1.02B
908.35M
749.85M
1.92B
1.46B
Tax Provision
209.93M
167.64M
121.30M
245.17M
225.32M
Net Income Common Stockholders
761.52M
695.38M
580.40M
1.65B
1.24B
Basic EPS
1.31
1.19
0.98
2.79
2.08
Diluted EPS
1.31
1.19
0.98
2.79
2.08
Basic Average Shares
581.75M
584.35M
592.25M
591.65M
596.24M
Diluted Average Shares
581.75M
584.35M
592.25M
591.65M
596.24M
Total Operating Income as Reported
1.03B
914.86M
817.97M
1.98B
1.48B
Rent Expense Supplemental
--
139.38M
118.91M
152.19M
152.73M
Total Expenses
8.53B
8.00B
7.25B
9.16B
6.73B
Net Income from Continuing & Discontinued Operation
761.52M
695.38M
580.40M
1.65B
1.24B
Normalized Income
968.28M
885.96M
840.39M
1.99B
1.27B
Interest Income
111.55M
117.10M
133.91M
123.91M
137.98M
Interest Expense
59.15M
54.86M
63.44M
50.04M
434.84k
Net Interest Income
44.26M
59.02M
69.49M
70.50M
136.45M
EBIT
1.08B
963.21M
813.29M
1.97B
1.46B
EBITDA
1.08B
1.54B
1.35B
2.45B
1.84B
Reconciled Cost of Revenue
5.07B
4.73B
4.17B
5.97B
4.03B
Reconciled Depreciation
--
578.21M
540.39M
481.74M
376.71M
Net Income from Continuing Operation Net Minority Interest
761.52M
695.38M
580.40M
1.65B
1.24B
Total Unusual Items Excluding Goodwill
-260.42M
-233.71M
-310.16M
-390.94M
-39.51M
Total Unusual Items
-260.42M
-233.71M
-310.16M
-390.94M
-39.51M
Normalized EBITDA
1.34B
1.78B
1.66B
2.84B
1.88B
Tax Rate for Calcs
0.21
0.18
0.16
0.13
0.15
Tax Effect of Unusual Items
-53.66M
-43.13M
-50.17M
-49.93M
-6.09M
12/31/2021 - 9/17/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade